266 related articles for article (PubMed ID: 28391613)
1. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
2. Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report.
Ngo L; Miller E; Valen P; Gertner E
J Med Case Rep; 2018 Feb; 12(1):48. PubMed ID: 29478412
[TBL] [Abstract][Full Text] [Related]
3. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.
Gauci ML; Baroudjian B; Laly P; Madelaine I; Da Meda L; Vercellino L; Bagot M; Lioté F; Pages C; Lebbé C
Semin Arthritis Rheum; 2017 Oct; 47(2):281-287. PubMed ID: 28438383
[TBL] [Abstract][Full Text] [Related]
4. Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti-CTLA-4 and Anti-Programmed Death 1 Combination Treatment.
Amini-Adle M; Piperno M; Tordo J; Thomas L; Dalle S; Dubois V; Marabelle A
Arthritis Rheumatol; 2018 Aug; 70(8):1358. PubMed ID: 29579372
[No Abstract] [Full Text] [Related]
5. Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report.
Filetti M; Anselmi E; Macrini S; Rizzo F; Iacono D; Giusti R; Marchetti P
Semin Arthritis Rheum; 2018 Oct; 48(2):e17-e20. PubMed ID: 29402438
[No Abstract] [Full Text] [Related]
6. Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma.
Bas O; Ozbek A; Guven D; Aktepe O; Kılıc L; Kertmen N; Erman M
J Oncol Pharm Pract; 2020 Jul; 26(5):1230-1233. PubMed ID: 31735133
[TBL] [Abstract][Full Text] [Related]
7. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
Korman AM; Tyler KH; Kaffenberger BH
Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
[No Abstract] [Full Text] [Related]
8. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
[No Abstract] [Full Text] [Related]
9. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
10. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
11. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
[No Abstract] [Full Text] [Related]
12. Immune Checkpoint Inhibitor-Associated Remitting Seronegative Symmetrical Synovitis With Pitting Edema: Description of a New Entity by CanRIO.
Rouhi A; Jamal S; Arreola LG; Moon D; Hudson M; Roberts J; Ladouceur A; Ye C
J Rheumatol; 2024 May; 51(5):523-528. PubMed ID: 38428960
[TBL] [Abstract][Full Text] [Related]
13. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
14. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
15. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
[No Abstract] [Full Text] [Related]
16. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
Wernham AGH; Shah F; Velangi S
Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
[No Abstract] [Full Text] [Related]
17. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
[No Abstract] [Full Text] [Related]
18. 79-year Old Man on Nivolumab with Itchy Erythematous Patches.
Copur MS; Corey S
Oncology (Williston Park); 2020 Feb; 34(2):53-54. PubMed ID: 32645195
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
20. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
